Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01746407 · ClinicalTrials.gov registry record
Procurement of Human Specimens for the Evaluation of Early Markers of Sepsis
A clinical trial, sponsored by Abbott Diagnostics Division.
- Completed
- Registry status
- 872
- Enrollment target
NCT01746407: Completed study, sponsored by Abbott Diagnostics Division.
NCT01746407 is a clinical trial that has completed, run by Abbott Diagnostics Division. The registered enrollment target is 872 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01746407 has completed, sponsored by Abbott Diagnostics Division.
- COMPLETED
- Registry status
- 872 participants
- Enrollment target
Study Summary
Procure blood specimens from individuals presenting to the emergency department (ED) with signs and /or symptoms of systemic infection or sepsis. The samples will be used for research and development activities related to sepsis, infections, etc.
Primary Outcome
Assessment of the progression of infection to severe sepsis in an ED population who present with signs or symptoms of infection.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 872 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-12 |
What the finished NCT01746407 record still lists
NCT01746407 is an observational study that tracks outcomes without assigning an intervention. The registered 872 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01746407 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01746407 about?
NCT01746407 is a clinical study titled "Procurement of Human Specimens for the Evaluation of Early Markers of Sepsis". Procure blood specimens from individuals presenting to the emergency department (ED) with signs and /or symptoms of systemic infection or sepsis. The samples will be used for research and development activities related to sepsis, infections, etc.
What is the current status of trial NCT01746407?
This trial is currently completed. The enrollment target is 872 participants. The study started on 2012-12. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01746407?
This trial is sponsored by Abbott Diagnostics Division, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT07076199 · 877 participants · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia